Serina Therapeutics Appoints Farrell Simon to its Board of Directors

Impact · against what's priced in

The appointment of Farrell Simon to Serina's board provides a modest positive catalyst due to his specific track record of raising over $400 million in capital, which reduces perceived funding risk for the development of SER-252. The confirmation of the Phase 1b registrational study design reinforces the clinical trajectory of the lead asset.

SER+0.30

No priced-in read yet

In context

The addition of a board member with a proven history of securing $400 million in funding from top-tier investors suggests improved capital-raising capabilities for the company's POZ platform and SER-252 program.

Read from the article alone

• pharmaceuticals
• SER
• biotechnology
• board appointment
• clinical trials
• drug delivery
• governance
• parkinsons disease

Search tags